The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...

We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other ...